However, we did not report any outcomes concerning spasticity, because there have been no RCTs evaluating the effects of dalfampridine on spasticity of patients with MS. BiCNU and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Researchers found that women who switched to Aromasin from tamoxifen were more likely to stay cancer-free than those who kept taking tamoxifen Abnormal images included those with asymmetrical uptake, or reduced uptake in both right and left putamen alone or also in the caudate nuclei.